NYSEAMERICAN:OCX - OncoCyte Stock Price, Forecast & News

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). View OncoCyte's Earnings History.

OncoCyte is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for OncoCyte.

2 brokers have issued twelve-month price targets for OncoCyte's shares. Their forecasts range from $7.00 to $7.75. On average, they anticipate OncoCyte's share price to reach $7.38 in the next twelve months. This suggests a possible upside of 158.8% from the stock's current price. View Analyst Price Targets for OncoCyte.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Headlines about OCX stock have trended positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OncoCyte earned a news impact score of 2.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for OncoCyte.

OncoCyte saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,160,000 shares, a drop of 7.2% from the January 15th total of 1,250,000 shares. Based on an average daily volume of 290,900 shares, the short-interest ratio is currently 4.0 days. Approximately 2.5% of the shares of the company are short sold. View OncoCyte's Current Options Chain.

Some companies that are related to OncoCyte include Cel-Sci (CVM), Bellus Health (BLU), Starpharma (SPL), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Pfenex (PFNX), Biotest (BIO), Trillium Therapeutics (TRIL), Silence Therapeutics (SLN), Rafael (RFL), ProMetic Life Sciences (PLI), IMV (IMV), Neuren Pharmaceuticals (NEU), Resverlogix (RVX) and Theratechnologies (TH).

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), BioTime (BTX), Anavex Life Sciences (AVXL), Geron (GERN), Alnylam Pharmaceuticals (ALNY), Progenics Pharmaceuticals (PGNX), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), Novocure (NVCR) and Matinas BioPharma (MTNB).

OncoCyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (3.92%), State Street Corp (0.84%), Geode Capital Management LLC (0.60%), P.A.W. Capital Corp (0.48%), Penbrook Management LLC (0.34%) and Barclays PLC (0.33%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Institutional Ownership Trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, AQR Capital Management LLC and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for OncoCyte.

OCX stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Penbrook Management LLC, Barclays PLC, Oxford Asset Management LLP, Virtu Financial LLC, State Street Corp, UBS Group AG and Geode Capital Management LLC. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Insider Buying and Selling for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $2.85.

OncoCyte has a market capitalization of $148.12 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

The official website for OncoCyte is http://www.oncocyte.com/.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.